[18f] Choline Βιοκοσμοσ

Fluorocholine (18F) is a radiopharmaceutical used in PET imaging to evaluate metabolic activity. It is commonly used for detecting prostate cancer and other conditions. This product is manufactured by Biokosmos SA and is intended for intravenous administration.

Fluorocholine (18F) is primarily used in positron emission tomography (PET) imaging to assess metabolic activity in tissues. It is often employed in the evaluation of prostate cancer recurrence or metastasis, as well as in imaging of other cancers where choline metabolism is elevated. The radiopharmaceutical helps clinicians identify areas of abnormal metabolic activity that may require further investigation.

As a radiopharmaceutical, Fluorocholine (18F) works by being taken up by cells with high metabolic rates, such as cancer cells. Once administered, it accumulates in tissues where choline metabolism is active, making these areas visible on PET scans. The effects are localized to the imaging process and do not produce direct therapeutic actions.

Fluorocholine (18F) should only be handled and administered by trained medical professionals in a controlled clinical setting. Patients should inform their healthcare provider of any allergies, especially to previous imaging agents. Pregnant or breastfeeding individuals should avoid exposure unless medically necessary, as radiation may pose risks.

No specific drug interactions have been widely reported with Fluorocholine (18F), as it is a diagnostic agent rather than a therapeutic drug. However, patients should disclose all medications, supplements, or recent imaging procedures to their healthcare provider. Certain conditions or medications may require adjustments to imaging protocols.